Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2013	Aug. 07, 2013
Document And Entity Information
Entity Registrant Name	TherapeuticsMD, Inc.
Entity Central Index Key	0000025743
Document Type	10-Q
Document Period End Date	Jun. 30, 2013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		131,212,706
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2013

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Current Assets:
Cash	$ 34,435,468	$ 1,553,474
Accounts receivable, net of allowance for doubtful accounts of $100,385 and $42,408, respectively	957,779	606,641
Inventory	1,506,059	1,615,210
Other current assets	3,607,283	751,938
Total current assets	40,506,589	4,527,263
Fixed assets, net	76,494	65,673
Other Assets:
Prepaid expense	1,980,519	953,655
Intangible assets	345,238	239,555
Security deposit	156,949	31,949
Total other assets	2,482,706	1,225,159
Total assets	43,065,789	5,818,095
Current Liabilities:
Accounts payable	2,045,116	1,641,366
Deferred revenue	1,219,072	1,144,752
Other current liabilities	1,334,730	725,870
Total current liabilities	4,598,918	3,511,988
Long-Term Liabilities:
Notes payable, net of debt discount of $0 and $1,102,680, respectively		3,589,167
Accrued Interest		150,068
Total Long-term liabilities		3,739,235
Total liabilities	4,598,918	7,251,223
Commitments and Contingencies
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 250,000,000 shares authorized; 131,212,706 and 99,784,982 issued and outstanding, respectively	131,213	99,785
Additional paid-in capital	102,834,270	50,580,400
Accumulated deficit	(64,498,612)	(52,113,313)
Total stockholder' deficit	38,466,871	(1,433,128)
Total liabilities and stockholders' deficit	$ 43,065,789	$ 5,818,095

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 100,385	$ 42,048
Debt discount on notes payable		$ 1,102,680
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	131,212,706	99,784,982
Common stock, shares outstanding	131,212,706	99,784,982

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Income Statement [Abstract]
Revenues, net	$ 2,080,885	$ 819,150	$ 3,618,080	$ 1,540,842
Cost of goods sold	463,606	372,370	843,952	708,494
Gross profit	1,617,279	446,780	2,774,128	832,348
Operating expenses:
Sales, general, and administration	5,476,553	3,573,485	10,003,135	6,400,535
Research and development	1,747,084	833,342	3,312,285	1,245,303
Depreciation and amortization	10,636	14,535	18,593	29,113
Total operating expense	7,234,273	4,421,362	13,334,013	7,674,951
Operating loss	(5,616,994)	(3,974,582)	(10,559,885)	(6,842,603)
Other income (expense)
Miscellaneous income	3,479	1,554	3,479	1,554
Interest expense	(150)	(1,148,761)	(1,165,981)	(1,250,734)
Financing costs	(395,981)		(659,968)
Loan guaranty costs		(11,745)	(2,944)	(23,490)
Beneficial conversion feature		(6,716,504)		(6,716,504)
Loss on extinguishment of debt				(10,307,864)
Total other income (expense)	(392,652)	(7,875,456)	(1,825,414)	(18,297,038)
Loss before taxes	(6,009,646)	(11,850,038)	(12,385,299)	(25,139,641)
Provision for income taxes
Net loss	$ (6,009,646)	$ (11,850,038)	$ (12,385,299)	$ (25,139,641)
Net loss per share, basic and diluted	$ (0.05)	$ (0.14)	$ (0.11)	$ (0.29)
Weighted average number of shares outstanding	130,851,978	86,149,419	116,866,764	85,352,818

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Statement of Cash Flows [Abstract]
Net loss	$ (12,385,299)	$ (25,139,641)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	12,084	15,141
Amortization of intangible assets	6,509	13,972
Provision for doubtful accounts	58,337	15,023
Amortization of debt discount	1,102,680	1,109,276
Stock based compensation	1,179,912	529,129
Amortization of deferred financing costs	659,938
Stock based expense for services	637,155	120,120
Loan guaranty costs	2,944	23,490
Loss on debt extinguishment		10,307,864
Beneficial conversion feature		6,716,504
Changes in operating assets and liabilities
Accounts receivable	(409,475)	(396,232)
Inventory	109,151	(232,168)
Other current assets	(1,696,551)	(118,566)
Other assets	(899,000)
Accounts payable	403,750	385,620
Accrued interest	(150,068)	133,702
Other current liabilities	608,860	248,450
Deferred revenue	74,320	618,877
Net cash flows used in operating activities	(10,684,753)	(5,649,439)
CASH FLOWS FROM INVESTING ACTIVITIES
Payment of security deposit	(125,000)
Patent costs, net of abandoned costs	(112,192)	(49,184)
Purchase of property and equipment	(22,905)	(66,404)
Net cash flows used in investing activities	(260,097)	(115,588)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock, net	48,512,460
Proceeds from notes and loans payable		6,900,000
Repayment of notes payable	(4,691,847)	(50,780)
Repayment of notes payable - related party		(50,000)
Proceeds from exercise of options	6,231	165,999
Proceeds from line of credit	500,000
Repayment of line of credit	(500,000)
Proceeds from sale of warrants		400
Net cash flows provided by financing activities	43,826,844	6,965,619
Increase in cash	32,881,994	1,200,592
Cash, beginning of period	1,553,474	126,421
Cash, end of period	34,435,468	1,327,013
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	212,853	7,756
Cash paid for income taxes
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES
Warrants issued for financing	1,711,956	2,509,537
Warrants issued in exchange for debt and accrued interest		3,102,000
Warrants issued for services	462,196	1,532,228
Shares issued in exchange for debt and accrued interest		1,054,658
Notes payable issued for accrued interest		$ 15,123

THE COMPANY	6 Months Ended
THE COMPANY	Jun. 30, 2013
Company
THE COMPANY	NOTE 1 – THE COMPANY TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company organized on May 13, 2008, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation incorporated on January 10, 2012, or BocaGreen. Unless the context otherwise requires, TherapeuticsMD, VitaMed, and BocaGreen collectively are sometimes referred to as “our company,” “we,” “our,” or “us.” Nature of Business We are a women’s healthcare product company focused on creating and commercializing products targeted exclusively for women. We currently manufacture and distribute branded and generic prescription prenatal vitamins as well as over-the-counter vitamins and cosmetics.

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

6 Months Ended

Jun. 30, 2013

Basis Of Presentation And Recently Issued Accounting Pronouncements

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

NOTE 2 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Interim Financial Statements

Our accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles, or GAAP, for complete financial statements. In our opinion, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC. The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2012.

Fair Value of Financial Instruments

Our financial instruments consist primarily of receivables, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered Level 1 assets under the fair value hierarchy. Interest rates that are currently available to us for issuance of short and long-term debt with similar terms and remaining maturities are used to estimate the fair value of our short and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.

Fair Value of Financial Instruments

We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC 820 Fair Value Measurements and Disclosures. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:

	Level 1		unadjusted quoted prices in active markets for identical assets or liabilities;

	Level 2		quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and

	Level 3		unobservable inputs for the asset or liability.

At June 30, 2013 and December 31, 2012, we had no assets or liabilities that were valued at fair value on a recurring basis.

Research and Development

Research and development, or R&D, expenses include internal R&D activities, external contract research organization, or CRO, services and their clinical research sites, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO’s based on agreed upon terms and may include payments in advance of a study starting date. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.

Earnings Per Share

We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts, basic and diluted. We compute basic EPS based on the weighted average number of shares of common stock outstanding during the period. We compute diluted EPS based on the weighted average number of shares of common stock outstanding plus all potentially dilutive common shares outstanding during the period. Such potentially dilutive common shares consist of stock options and warrants. Potentially dilutive common shares totaling 21,773,002 and 18,884,154 at June 30, 2013 and 2012, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to the net loss reported by us.

Recently Issued and Newly Adopted Accounting Pronouncements

On July 18, 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have an impact on our condensed consolidated financial statements.

Reclassifications

Certain 2012 amounts have been reclassified to conform to current year presentation.

OTHER CURRENT ASSETS

6 Months Ended

Jun. 30, 2013

Other Current Assets

OTHER CURRENT ASSETS

NOTE 4 – OTHER CURRENT ASSETS

Other current assets consist of the following:

	June 30, 2013		December 31, 2012
Prepaid research and development costs	$	1,686,254	$	189,375
Deferred financing costs		1,051,988		-0-
Prepaid consulting		541,936		432,216
Other receivables-related party (Note 12)		171,261		-0-
Prepaid insurance		125,266		127,403
Other prepaid costs		30,578		-0-
Prepaid guaranty costs		-0-		2,944
TOTAL OTHER CURRENT ASSETS	$	3,607,283	$	751,938

OTHER ASSETS

6 Months Ended

Jun. 30, 2013

Other Assets:

OTHER ASSETS

NOTE 6 – OTHER ASSETS

Prepaid expense consists of the following:

	June 30, 2013		December 31, 2012
Prepaid manufacturing costs	$	899,000	$	-0-
Prepaid consulting expense		1,081,519		953,655
TOTAL PREPAID EXPENSE	$	1,980,519	$	953,655

Intangible assets consist of the following:

	June 30, 2013		December 31, 2012
Patent costs	$	337,163	$	224,971
Website costs, net of amortization of $83,668 and $77,159, respectively		8,075		14,584
TOTAL INTANGIBLE ASSETS	$	345,238	$	239,555

Amortization expense for the six months ended June 30, 2013 and 2012 was $6,509 and $13,972, respectively.

OTHER CURRENT LIABILITIES

6 Months Ended

Jun. 30, 2013

Other Current Liabilities

OTHER CURRENT LIABILITIES

NOTE 7 – OTHER CURRENT LIABILITIES

Other current liabilities consist of the following:

	June 30, 2013		December 31, 2012
Accrued offering costs	$	500,000	$	-0-
Accrued payroll and commission costs		228,877		397,210
Accrued vacation costs		263,851		114,899
Accrued professional fees		120,250		90,000
Allowance for coupons and returns		86,540		53,002
Other accrued expenses		93,853		29,400
Dividends payable(1)		41,359		41,359
TOTAL OTHER CURRENT LIABILITIES	$	1,334,730	$	725,870

______________

(1) In June 2008, the Company declared and paid a special dividend of $0.40 per share of common stock to all stockholders of record as of June 10, 2008. This amount reflects unclaimed dividends by certain stockholders.

NOTES PAYABLE	6 Months Ended
NOTES PAYABLE	Jun. 30, 2013
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 8 – NOTES PAYABLE Issuance and Payment of Multiple Advance Revolving Credit Note On January 31, 2013, we entered into a business loan agreement with Plato and Associates, LLC, a Florida limited liability company, or Plato, for a Multiple Advance Revolving Credit Note, or the Plato Note. The Plato Note allows us to draw down funding up to the $10 million maximum principal amount, at a stated interest rate of 6% per annum. Plato may make advances to us from time to time under the Plato Note at our request, which advances will be of a revolving nature and may be made, repaid, and made from time to time. Interest payments shall be due and payable on the tenth day following the end of each calendar quarter in which any interest is accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the Plato Note, together with all accrued interest and other amounts payable under the Plato Note, if any, will be due and payable on February 24, 2014. The Plato Note is secured by substantially all of our assets. On each of February 25 and March 13, 2013, $200,000 was drawn against the Plato Note. On March 21, 2013, we repaid $401,085, including accrued interest, and as of June 30, 2013, there was no balance outstanding under the Plato Note. As additional consideration for the Plato Note, we issued Plato a warrant to purchase 1,250,000 shares of our common stock at an exercise price $3.20 per share (see NOTE 9 – STOCKHOLDERS’ EQUITY for more details). Borrowing Under Amended Bank LOC In February 2013, we borrowed $100,000 from First United Bank under the Amended Bank LOC. The Amended Bank LOC required a personal guarantee and cash collateral limited to $100,000 which was provided by Reich Family Limited Partnership, or Reich Family LP, an entity controlled by Mitchell Krassan, an officer of the Company. On April 25, 2013, we paid the principal and interest due under the Amended Bank LOC of $100,735. On May 1, 2013, the Amended Bank LOC expired and was not renewed. Accordingly, the personal guarantee was canceled and the cash collateral was refunded to Reich Family LP. Issuance of Promissory Notes In January and February 2012, we sold 6% promissory notes for an aggregate of $900,000 with due dates of March 1, 2012. As discussed below in Issuance and Settlement of February 2012 Notes, these promissory notes were modified on February 24, 2012 through the issuance of secured promissory notes, or the February 2012 Notes. Issuance and Settlement of February 2012 Notes On February 24, 2012, we issued the February 2012 Notes to an individual and an entity, or the Parties, both of which are our stockholders, in the principal base amount of $1,358,014 and $1,357,110, respectively, and granted warrants for the purchase in the aggregate of 9,000,000 shares of our common stock, or the February 2012 Warrants, pursuant to the terms of a Note Purchase Agreement, also dated February 24, 2012. As consideration for the February 2012 Notes and the February 2012 Warrants, we received an aggregate of $1,000,000 of new funding from the Parties and the Parties surrendered certain promissory notes previously issued by us in the aggregate amount of $1,700,000 plus accrued interest of $15,124. Under the February 2012 Notes, the Parties loaned us an additional $3,000,000 during March, April, and May 2012. On June 19, 2012, we settled $3,102,000 in principle and interest of the February 2012 Notes in exchange for the exercise of 8,145,486 warrants. As discussed below in Issuance and Payment of June 2012 Notes, the remaining balance of $2,691,847 of the February 2012 Notes was modified on June 19, 2012 through the issuance of secured promissory notes, or the June 2012 Notes, (see NOTE 9 – STOCKHOLDERS’ EQUITY, Warrants Issued in Connection with Debt, for more details). Issuance and Payment of June 2012 Notes On June 19, 2012, we issued the June 2012 Notes to the Parties in the principal base amounts of $2,347,128 and $2,344,719, respectively, pursuant to the terms of a note purchase agreement, or the June 2012 Note Purchase Agreement. As consideration for the June 2012 Notes, the Parties surrendered the remaining balance of the February 2012 Notes in the aggregate amount of $1,347,128 and $1,344,719, respectively (which sums included principle and interest through June 19, 2012), and we received an aggregate of $2,000,000 of new funding from the Parties (the “June Funding”). The principal base amount of each of the June 2012 Notes, plus any additional advance made to us thereafter, together with accrued interest at the annual rate of 6%, was due in one lump sum payment on February 24, 2014. As security for our obligations under the June 2012 Note Purchase Agreement and the June 2012 Notes, we entered into a security agreement and pledged all of our assets, tangible and intangible, as further described therein. We also granted warrants to purchase an aggregate of 7,000,000 shares of our common stock in connection with the June Funding. On March 21, 2013, we repaid $4,882,019 including accrued interest, leaving a balance of $21,595 in accrued interest as of March 31, 2013 related to the June 2012 Notes. On April 25, 2013, the balance of accrued interest was paid in full.

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2013

Stockholders' Deficit:

STOCKHOLDERS' EQUITY

NOTE 9 – STOCKHOLDERS’ EQUITY

Common Stock

At June 30, 2013, we had 250,000,000 shares of common stock, $0.001 par value per share, authorized with 131,212,706 shares issued and outstanding.

Public Offering

On March 14, 2013, we entered into an underwriting agreement, or the Underwriting Agreement, with Jefferies LLC, as representative of the underwriters named therein, or the Underwriters, relating to the issuance and sale of 29,411,765 shares of our common stock. The price to the public in the offering was $1.70 per share and the Underwriters agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $1.581 per share. The net proceeds to us from this offering was approximately $45.4 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. In addition, under the terms of the Underwriting Agreement, we granted the Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of common stock. The offering closed on March 20, 2013.

Additional Shares Purchased under Offering

As part of the public offering of our common stock described in Public Offering above, on April 12, 2013, the Underwriters exercised their option to purchase an additional 1,954,587 shares of our common stock to cover over-allotments. We issued these shares to the Underwriters on April 18, 2013 and received proceeds of approximately $3.1 million, net of expenses.

Warrants to Purchase Common Stock of the Company

As of June 30, 2013, we had common stock purchase warrants outstanding for an aggregate of 14,293,499 shares of our common stock with a weighted average contractual remaining life of 4.8 years and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.86 per share.

The valuation methodology used to determine the fair value of our Warrants is the Black-Scholes-Merton option-pricing model, or Black-Scholes Model, an acceptable model in accordance with ASC 718-10, Compensation – Stock Compensation. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the Warrant.

Warrants Issued in Connection with Debt

On January 31, 2013, we granted a warrant for the purchase of 1,250,000 shares of our common stock in connection with the issuance of the Plato Note, or the Plato Warrant, (see NOTE 8 – NOTES PAYABLE, Issuance of Multiple Advance Revolving Credit Note). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant will vest and become exercisable on October 31, 2013 and may be exercised any time after that date prior to the January 31, 2019 expiration date of the Plato Warrant. This Warrant, with a fair value of approximately $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. At June 30, 2013, $1,051,988 was reported as deferred financing costs included in other current assets in the accompanying condensed consolidated balance sheet and is being amortized over the life of the Plato Note. For the six months ended June 30, 2013, $659,938 was recorded as financing costs on the accompanying condensed consolidated financial statements.

On June 19, 2012, we granted warrants for the purchase of an aggregate of 7,000,000 shares of our common stock in connection with the issuance of the June 2012 Notes, or the June 2012 Warrants, (see NOTE 8 – NOTES PAYABLE, Issuance of June 2012 Notes). Of the June 2012 Warrants issued, 6,000,000 are exercisable at $2.00 per share and 1,000,000 are exercisable at $3.00 per share. The fair value of the June 2012 Warrants of $9,424,982 was determined by using the Black-Scholes Model on the date of the grant using a term of 5 years; a volatility of 44.64%; risk free rate of 0.75%; and a dividend yield of 0%. The relative fair value of the June 2012 Warrants of $1,649,890 was determined by using the relative fair value calculation method on the date of the grant. As a result of the repayment of the associated debt on March 21, 2013, we expensed the remaining unamortized debt discount of $885,709 at the time of the repayment.

On February 24, 2012, we issued warrants for the purchase of an aggregate of 5,685,300 shares of our common stock in connection with the modification of certain existing promissory notes, or the Modification Warrants, and warrants for the purchase of an aggregate of 3,314,700 shares of our common stock in connection with the issuance of the February 2012 Notes (the “February 2012 Warrants”) (see NOTE 8 – NOTES PAYABLE, Issuance of February 2012 Notes). Both the Modification Warrants and the February 2012 Warrants are exercisable at $0.38 per share. The Modification Warrants’ fair value of $10,505,247 and the February 2012 Warrants’ fair value of $6,124,873 was determined by using the Black-Scholes Model on the date of the grant using a term of 5 years; a volatility of 44.5%; risk free rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification Warrants as part of the loss on extinguishment of debt in the accompanying condensed consolidated financial statements. The relative fair value of the February 2012 Warrants of $859,647 was recorded as debt discount. As a result of the surrender of the February 2012 Notes on June 19, 2012, we expensed the remaining unamortized debt discount.

Warrants Issued for Services

On May 7, 2013, we entered into a consulting agreement, or the Agreement, with Sancilio & Company, Inc., or SCI, to develop drug platforms to be used in hormone replacement drug products, or the Drug Products. These services include support of our efforts to successfully obtain U.S. Federal Drug Administration, or FDA, approval for the Drug Products, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the Agreement, SCI agreed to forfeit its rights to receive warrants for the purchase of an aggregate of 833,000 shares of our common stock that were to be issued pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the Agreement, we agreed to issue SCI a warrant to purchase 850,000 shares of our common stock that vest as follows:

283,333 shares were earned on May 11, 2013 upon successful filing of the IND application with the FDA for the Drug Product for an estradiol-based product in a softgel vaginal capsule for the treatment of VVA. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of the vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as consulting expense in the accompanying condensed consolidated financial statements,

283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. We recorded $154,068 as prepaid expense-short term and $308,128 as prepaid expense-long term in the accompanying condensed consolidated financial statements. We will begin amortizing this expense monthly over 3 years beginning in July 2013, and

283,334 shares will vest upon the receipt by us of any final FDA approval of a Drug Product that SCI helped us design. It is anticipated that this event will not occur before December 2015.

In March 2012, we issued a warrant for the purchase of an aggregate of 31,000 shares of our common stock to five unaffiliated individuals for services rendered. These warrants were valued on the date of the grant using a term of 5 years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield of 0%; $29,736 was recorded as consulting expense in the accompanying condensed consolidated financial statements.

A summary of our warrant activity and related information for 2013 follows:

	Number of Shares Under Company Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2012		12,193,499	$	1.63		4.8	$	17,971,994
Granted		2,100,000	$	2.72		7.3	$	867,000
Exercised		-0-
Expired		-0-
Cancelled		-0-
Balance at June 30, 2013		14,293,499	$	1.79		4.8	$	17,985,449
Vested and Exercisable at June 30, 2013		12,149,559	$	1.67		4.3	$	16,540,175

As of June 30, 2013, we had warrants outstanding with exercise prices ranging from $0.24 to $3.20 per share. As of June 30, 2013, unamortized costs associated with warrants totaled approximately $3,995,000.

Stock Options

In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or LTIP, to provide financial incentives to our employees, members of our Board, and our advisers and consultants who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the LTIP consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, EVA awards, and other stock or cash awards as described in the LTIP. There are 25,000,000 shares authorized for issuance under the LTIP. Under this LTIP, non-qualified stock options for the purchase of an aggregate of 12,934,725 shares of our common stock were outstanding at June 30, 2013.

On February 23, 2012, the Board adopted the 2012 Stock Incentive Plan, a non-qualified plan not requiring approval by our stockholders, or the 2012 SOP. The 2012 SOP was designed to serve as an incentive for retaining qualified and competent key employees, officers and directors, and certain consultants and advisors. There are 10,000,000 shares authorized for issuance under the 2012 SOP and non-qualified stock options for the purchase of an aggregate of 1,625,000 shares of our common stock were outstanding at June 30, 2013.

The valuation methodology used to determine the fair value of the stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model during the six months ended June 30, 2013 are set forth in the table below.

	Six Months Ended June 30, 2013			Year Ended December 31, 2012
Risk-free interest rate		0.65-1.42	%		0.61-2.23	%
Volatility		33.35-45.76	%		40.77-46.01	%
Term (in years)		5-6.25			5-6.25
Dividend yield		0.00	%		0.00	%

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual term of the option using the simplified method.

On June 28, 2013, an individual exercised his stock option to purchase an aggregate of 61,372 shares of our common stock for an aggregate purchase price of $6,251.

On June 21, 2013, we issued 10-year stock options to employees and consultants for the purchase of an aggregate of 632,500 shares with an exercise price of $2.98. An aggregate of 232,500 shares available under the stock options vest over a 3-year period on the anniversary of issuance, an aggregate of 100,000 shares vest monthly over an 18 month period, and an aggregate of 300,000 shares vest monthly over a 3-year period.

On May 10, 2013, we issued 10-year stock options to employees for the purchase of an aggregate of 100,000 shares with an exercise price of $2.71. An aggregate of 50,000 shares available under the stock options vest over a 4-year period on the anniversary of issuance and an aggregate of 50,000 shares vested immediately.

On May 6, 2013, we issued a 10-year stock option to a consultant for the purchase of an aggregate of 96,068 shares with an exercise price of $2.96. The shares available under the stock options vest monthly over a 12-month period.

On May 2, 2013, the Compensation Committee of the Board recommended the granting of stock options to our directors. The Board approved the recommendation and we issued 10-year stock options for the purchase of an aggregate of 575,000 shares of our common stock with an exercise price of $2.80, as follows: (i) a stock option for the purchase of 225,000 shares of our common stock to the Chairman of the Board; (ii) a stock option for the purchase of 75,000 shares of our common stock to the chair of each committee of the board; and (ii) an Option for the purchase of 50,000 shares of our common stock to each of the remaining directors. All of these stock options vest on December 31, 2013.

On May 8, 2013, Robert Finizio, our Chief Executive Officer, forfeited his contractual right to receive 600,000 shares upon exercise of a stock option granted in connection with his employment agreement as well as his right to receive any future stock options. Mr. Finizio gave up these rights with the understanding that these stock options would be returned to the pool of stock options available for issuance to attract future employees.

On March 29, 2013, we issued 10-year stock options to employees and consultants for the purchase of an aggregate of 180,109 shares with exercise prices ranging from $1.70 to $2.70. An aggregate of 500 shares available under the stock options vest over a 4-year period on the anniversary of issuance, an aggregate of 12,500 shares vest monthly over a 1-year period, 92,109 shares vest monthly over a 13-month period from the date of issuance, and an aggregate of 75,000 shares vest as follows: an aggregate of 31,250 vest immediately and an aggregate of 43,750 vest monthly over the subsequent seven months.

On June 29, 2012, we issued 10-year stock options to employees, consultants, and a director for the purchase of an aggregate of 250,000 shares with an exercise price of $2.80. An aggregate of 7,500 shares available under the stock options vest over a 4-year period on the anniversary of issuance, an aggregate of 115,000 shares vest over a 2-year period on the anniversary of issuance, 2,500 shares vest over a 1-year period on the anniversary of issuance, 75,000 shares vest monthly from December 31, 2012, and 50,000 vest immediately.

On April 16, 2012, the Board approved the issuance of 10-year stock options for our directors for the purchase of: (i) an aggregate of 350,000 shares (50,000 shares each) to our directors for services to be rendered during calendar year 2012 and (ii) an aggregate of 75,000 shares (25,000 shares each) to the chairs of the Audit, Compensation and Nominating and Corporate Governance Committees for services to be rendered during calendar year 2012. The stock options have an exercise price of $2.55 per share vested in full on December 31, 2012. In addition, Dr. Brian Bernick, a director and employee, was issued a stock option for 150,000 shares for services rendered as an employee, having an exercise price of $2.55, which vested in full on April 16, 2013.

On March 30, 2012, we issued 10-year stock options to employees and consultants for the purchase of an aggregate of 480,000 shares with an exercise price of $2.40. An aggregate of 405,000 shares available under the stock options vest over a 4-year period on the anniversary of issuance, an aggregate of 60,000 shares vest over a 2-year period on the anniversary of issuance, and 15,000 shares vest monthly over a 12-month period from the date of issuance.

On March 30, 2012, the Board approved a cashless exercise provision for use by holders of stock options. Also on March 30, 2012, an individual exercised his option to purchase 245,485 shares of our common stock. The aggregate purchase price of approximately $60,000 was paid pursuant to a cashless exercise provision wherein the individual surrendered his right to receive 25,000 shares thereunder.

On February 27, 2012, we issued stock options to our officers and directors for the purchase of an aggregate of 600,000 shares with an exercise price of $2.20 per share. The stock options vested in full on February 27, 2013.

In January 2012, certain individuals exercised their stock options to purchase an aggregate of 1,630,022 shares of our common stock for an aggregate purchase price of $166,000.

A summary of activity under the LTIP and 2012 SOP and related information follows:

	Number of Shares Under Company Option			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2012		13,733,488		$	1.16		7.7	$	26,804,117
Granted		1,583,677		$	2.79		9.9	$	365,845
Exercised		(61,372	)
Expired		-0-
Cancelled		(600,000	)
Balance at June 30, 2013		14,655,793		$	1.08		7.8	$	26,038,328
Vested and Exercisable at June 30, 2013		9,623,443		$	0.60		6.5	$	23,208,051

The weighted-average issue date fair value of stock options issued during the six months ended June 30, 2013 was $1.01.

At June 30, 2013, we had stock options outstanding with exercise prices ranging from $0.10 to $3.40 per share.

Share-based compensation expense for stock options recognized in our results for the six months ended June 30, 2013 and 2012 ($1,161,770 and $510,987, respectively) is based on awards vested and was estimated without forfeitures. ASC 718-10, requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates.

At June 30, 2013, total unrecognized estimated compensation expense related to non-vested stock options issued prior to that date was approximately $3,695,420 which is expected to be recognized over a weighted-average period of 1.49 years. No tax benefit was realized due to a continued pattern of operating losses.

INCOME TAXES	6 Months Ended
INCOME TAXES	Jun. 30, 2013
Income Taxes
INCOME TAXES	NOTE 10 – INCOME TAXES Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2013 as a result of (i) the losses recorded during the six months ended June 30, 2013, (ii) additional losses expected for the remainder of 2013, and/or (iii) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not" that some component or all of the benefits of deferred tax assets will not be realized. As of June 30, 2013, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.

RELATED PARTIES	6 Months Ended
RELATED PARTIES	Jun. 30, 2013
Related Parties
RELATED PARTIES	NOTE 11 – RELATED PARTIES Loan Guaranty In March 2011, VitaMed entered into a Business Loan Agreement and Promissory Note for a $300,000 bank line of credit, or the Bank LOC, for which the bank required personal guarantees and cash collateral. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of VitaMed, and by Reich Family LP, an entity controlled by Mitchell Krassan, also an officer of VitaMed. The Bank LOC accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012. On March 19, 2012, the bank and VitaMed negotiated a one year extension to the Bank LOC and a subsequent 2-month extension until May 1, 2013. In consideration for the personal guarantees and cash collateral, we issued warrants for an aggregate of 613,713 shares. On November 13, 2012, we entered into an amendment with the bank to reduce the Bank LOC to $100,000, or the Amended Bank LOC. As part of the Amended Bank LOC, the personal guarantees and cash collateral for Mr. Finizio and Mr. Milligan were released. In accordance with the terms of the warrants, the warrants previously granted to Mr. Finizio and Mr. Milligan were amended to reflect the amount vested prior to the date of the Amended Bank LOC (179,000 each). At June 30, 2013, an aggregate of 562,571 warrants related to this loan guaranty were vested. In February 2013, we borrowed $100,000 under the Amended Bank LOC. The Amended Bank LOC required a personal guarantee and cash collateral limited to $100,000 which was provided by Reich Family LP. On April 25, 2013, we paid the principal and interest due under the Amended Bank LOC of $100,735. On May 1, 2013, the Amended Bank LOC expired and was not renewed. Accordingly, the personal guarantee was canceled and the cash collateral was returned to Reich Family LP Lock-Up Agreements As required by the terms of the merger agreement with VitaMed dated July 18, 2011, the Company entered into Lock-Up Agreements, or the Agreements, with stockholders covering the aggregate of 70,000,000 shares of our common stock issued pursuant to this merger or reserved for issuance pursuant to stock options and warrants. Each stockholder agreed that from the date of the Agreements until 18 months thereafter, or the Lock-Up Period, they would not make or cause any sale of our common stock. After the completion of the Lock-Up Period, each stockholder agreed not to sell or dispose of more than 2.5% of their aggregate common stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble Out Period. Upon the completion of the Dribble Out Period, the Agreements shall terminate. Purchases by Related Parties During the six months ended June 30, 2013 and 2012, we sold our products to Dr. Brian Bernick, our Chief Medical Officer and director, in the amounts of $0 and $1,440, respectively, while $0 and $1,272 in receivables related thereto remained outstanding at both June 30, 2013 and December 31, 2012, respectively. Agreements with Pernix Therapeutics, LLC On February 29, 2012, Cooper C. Collins, President and largest stockholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on the Board. The Company entered into a Stock Purchase Agreement with Pernix on October 4, 2011. From time to time, we have entered into agreements with Pernix in the normal course of business primarily for the purchase of inventory. During the six months ended June 30, 2013 and 2012, we made purchases of approximately $0 and $96,250, respectively, from Pernix. At June 30, 2013 and December 31, 2012, there were outstanding amounts due to Pernix of approximately $0 and $308,000, respectively. Additionally, there were amounts due to us from Pernix for legal fee reimbursement in regards to the Aceto litigation described below in the amounts of $171,261 and $0 for the periods ending June 30, 2013 and December 31, 2012, respectively.

BUSINESS CONCENTRATIONS	6 Months Ended
BUSINESS CONCENTRATIONS	Jun. 30, 2013
Business Concentrations
BUSINESS CONCENTRATIONS	NOTE 12 - BUSINESS CONCENTRATIONS We purchase our products from several suppliers with approximately 98% and 87% of our purchases were supplied from one vendor for the six months ended June 30, 2013 and 2012, respectively. We sell our prescription dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated from sales to two customers, Cardinal Health, Inc. and McKesson Corporation accounted for 62% and 36% of our recognized revenue for the six months ended June 30, 2013 and 2012, respectively.

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2013
Commitments And Contingencies
COMMITMENTS AND CONTINGENCIES	NOTE 13 – COMMITMENTS AND CONTINGENCIES Office Lease We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease commencing on July 1, 2013 and expiring on September 30, 2018. The lease stipulates, among other things, average base monthly rents of $28,442 (inclusive of estimated operating expenses) and sales tax, for a total future minimum payments over the life of the lease of $1,791,900. The rental expense related to our prior lease which expired June 30, 2013 totaled $60,168 and $56,918 for the six months ended June 30, 2013 and 2012, respectively. Litigation We are party to various legal actions arising in the ordinary course of business, including actions related to our intellectual property. While it is not feasible to determine the actual outcome of these actions at this time, we do not believe that these matters, including those described below, will have a material adverse effect on our consolidated financial condition, results of operations, or cash flows. Aceto Corporation On November 13, 2012, Aceto Corporation filed a lawsuit against TherapeuticsMD and Boca-Green in the United States District Court for the Southern District of Florida seeking to enjoin us from using the Quatrefolic product and trademarks, among other things. On July, 17, 2013, the Court dismissed Aceto Corporation’s Complaint with leave to file an Amended Complaint on or before August 5, 2013. Based on our assessment of the case which is in the discovery stage, we believe that the case is without merit and, as a result, should not have a material adverse effect on our consolidated financial condition, results of operations, or cash flows. Avion Pharmaceuticals, LLC On November 30, 2012, Avion Pharmaceuticals, LLC, filed a lawsuit against TherapeuticsMD and Boca- Green in the United States District Court for the Northern District of Georgia seeking to enjoin us from using the Prena1 name, among other things. Based on our assessment of the case which is in the discovery stage, we believe that the case is without merit and, as a result, should not have a material adverse effect on our consolidated financial condition, results of operations, or cash flows. For additional information on these litigation matters, see our Annual Report on Form 10-K for the year ended December 31, 2012.

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Policies)

6 Months Ended

Jun. 30, 2013

Basis Of Presentation And Recently Issued Accounting Pronouncements Policies

Interim Financial Statements

Fair Value of Financial Instruments

	Level 1		unadjusted quoted prices in active markets for identical assets or liabilities;

	Level 2		quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and

	Level 3		unobservable inputs for the asset or liability.

At June 30, 2013 and December 31, 2012, we had no assets or liabilities that were valued at fair value on a recurring basis.

Research and Development

Earnings Per Share

We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts, basic and diluted. We compute basic EPS based on the weighted average number of shares of common stock outstanding during the period. We compute diluted EPS based on the weighted average number of shares of common stock outstanding plus all potentially dilutive common shares outstanding during the period. Such potentially dilutive common shares consist of stock options and warrants. Potentially dilutive common shares totaling 21,773,002 and 18,884,154 at June 30, 2013 and 2012, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to the net loss reported by us.

Recently Issued and Newly Adopted Accounting Pronouncements

Reclassifications

Certain 2012 amounts have been reclassified to conform to current year presentation.

OTHER CURRENT ASSETS (Tables)

6 Months Ended

Jun. 30, 2013

Other Current Assets Tables

Schedule of Other Current Assets

Other current assets consist of the following:

	June 30, 2013		December 31, 2012
Prepaid research and development costs	$	1,686,254	$	189,375
Deferred financing costs		1,051,988		-0-
Prepaid consulting		541,936		432,216
Other receivables-related party (Note 12)		171,261		-0-
Prepaid insurance		125,266		127,403
Other prepaid costs		30,578		-0-
Prepaid guaranty costs		-0-		2,944
TOTAL OTHER CURRENT ASSETS	$	3,607,283	$	751,938

OTHER ASSETS (Tables)

6 Months Ended

Jun. 30, 2013

Other Assets Tables

Schedule of other assets

Prepaid expense consists of the following:

	June 30, 2013		December 31, 2012
Prepaid manufacturing costs	$	899,000	$	-0-
Prepaid consulting expense		1,081,519		953,655
TOTAL PREPAID EXPENSE	$	1,980,519	$	953,655

Schedule of intangible assets

Intangible assets consist of the following:

	June 30, 2013		December 31, 2012
Patent costs	$	337,163	$	224,971
Website costs, net of amortization of $83,668 and $77,159, respectively		8,075		14,584
TOTAL INTANGIBLE ASSETS	$	345,238	$	239,555

OTHER CURRENT LIABILITIES (Tables)

6 Months Ended

Jun. 30, 2013

Other Current Liabilities Tables

Schedule of other current liabilities

Other current liabilities consist of the following:

	June 30, 2013		December 31, 2012
Accrued offering costs	$	500,000	$	-0-
Accrued payroll and commission costs		228,877		397,210
Accrued vacation costs		263,851		114,899
Accrued professional fees		120,250		90,000
Allowance for coupons and returns		86,540		53,002
Other accrued expenses		93,853		29,400
Dividends payable(1)		41,359		41,359
TOTAL OTHER CURRENT LIABILITIES	$	1,334,730	$	725,870

______________

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2013

Stockholders Equity Tables

Schedule of warrant activity

A summary of our warrant activity and related information for 2013 follows:

	Number of Shares Under Company Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2012		12,193,499	$	1.63		4.8	$	17,971,994
Granted		2,100,000	$	2.72		7.3	$	867,000
Exercised		-0-
Expired		-0-
Cancelled		-0-
Balance at June 30, 2013		14,293,499	$	1.79		4.8	$	17,985,449
Vested and Exercisable at June 30, 2013		12,149,559	$	1.67		4.3	$	16,540,175

Schedule of assumptions used in the Black-Scholes Model

The assumptions used in the Black-Scholes Model during the six months ended June 30, 2013 are set forth in the table below.

	Six Months Ended June 30, 2013			Year Ended December 31, 2012
Risk-free interest rate		0.65-1.42	%		0.61-2.23	%
Volatility		33.35-45.76	%		40.77-46.01	%
Term (in years)		5-6.25			5-6.25
Dividend yield		0.00	%		0.00	%

Schedule of activity under the LTIP

A summary of activity under the LTIP and 2012 SOP and related information follows:

	Number of Shares Under Company Option			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2012		13,733,488		$	1.16		7.7	$	26,804,117
Granted		1,583,677		$	2.79		9.9	$	365,845
Exercised		(61,372	)
Expired		-0-
Cancelled		(600,000	)
Balance at June 30, 2013		14,655,793		$	1.08		7.8	$	26,038,328
Vested and Exercisable at June 30, 2013		9,623,443		$	0.60		6.5	$	23,208,051

INVENTORY (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Inventory
Finished Product	$ 1,100,486	$ 1,124,739
Raw Material	291,035	380,000
Deferred Costs	114,538	110,471
Inventory	$ 1,506,059	$ 1,615,210

OTHER CURRENT ASSETS (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Other Current Assets
Prepaid research and development costs	$ 1,686,254	$ 189,375
Deferred financing costs	1,051,988
Prepaid consulting	541,936	432,216
Other receivables - related party	171,261
Prepaid Insurance	125,266	127,403
Other prepaid costs	30,578
Prepaid guaranty costs		2,944
Other current assets	$ 3,607,283	$ 751,938

FIXED ASSETS (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Fixed assets, gross	$ 149,178	$ 126,273
Accumulated depreciation	(72,684)	(60,600)
Fixed Assets, net	76,494	65,673
Equipment
Fixed assets, gross	90,573	67,668
Furniture and Fixtures
Fixed assets, gross	46,625	46,625
Leasehold Improvements
Fixed assets, gross	$ 11,980	$ 11,980

OTHER ASSETS (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Other Assets
Prepaid manufacturing costs	$ 899,000
Prepaid consulting expense	1,081,519	953,655
Prepaid expense	$ 1,980,519	$ 953,655

OTHER CURRENT LIABILITIES (Details) (USD $)

Jun. 30, 2013

Dec. 31, 2012

Other Current Liabilities

Accrued offering costs

$ 500,000

Accrued payroll and commission costs

228,877

397,210

Accrued vacation costs

263,851

114,899

Accrued professional fees

120,250

90,000

Allowance for coupons and returns

86,540

53,002

Other accrued expenses

93,853

29,400

Dividends payable

41,359

^[1]

41,359

^[1]

Other current liabilities

$ 1,334,730

$ 725,870

[1]	In June 2008, we declared and paid a special dividend of $0.40 per share of common stock to all shareholders of record as of June 10, 2008. This amount reflects moneys remaining unclaimed by certain shareholders.

NOTES PAYABLE (Details Narrative) (USD $)	6 Months Ended		0 Months Ended	1 Months Ended		0 Months Ended	1 Months Ended		0 Months Ended		0 Months Ended		0 Months Ended		0 Months Ended		3 Months Ended			0 Months Ended
NOTES PAYABLE (Details Narrative) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Apr. 25, 2013 First United Bank Line of Credit	Feb. 28, 2013 First United Bank Line of Credit	Mar. 31, 2011 First United Bank Line of Credit	Jan. 31, 2013 Plato and Associates Note	Mar. 31, 2013 Plato and Associates Note	Feb. 28, 2013 Plato and Associates Note	Feb. 24, 2012 Promissory Notes	Feb. 28, 2012 Promissory Notes	Jun. 19, 2012 Promissory Note Individual - February 2012 Notes Issuance	Feb. 24, 2012 Promissory Note Individual - February 2012 Notes Issuance	Jun. 19, 2012 Promissory Note Entity - February 2012 Notes Issuance	Feb. 24, 2012 Promissory Note Entity - February 2012 Notes Issuance	Jun. 19, 2012 Promissory Notes - February 2012 Notes Issuance	Feb. 24, 2012 Promissory Notes - February 2012 Notes Issuance	May 31, 2012 Promissory Notes - February 2012 Notes Issuance	Jun. 19, 2012 Promissory Note Individual - June 2012 Notes Issuance	Jun. 19, 2012 Promissory Note Entity - June 2012 Notes Issuance	Mar. 21, 2013 Promissory Notes - June 2012 Notes Issuance	Jun. 19, 2012 Promissory Notes - June 2012 Notes Issuance	Mar. 31, 2013 Promissory Notes - June 2012 Notes Issuance
Debt Interest rate					3.02%	6.00%				6.00%	6.00%		6.00%
Promissory notes, principal						$ 10,000,000				$ 900,000		$ 1,358,014		$ 1,357,110				$ 2,347,128	$ 2,344,179
Proceeds from revolving credit note							200,000	200,000
Repayment of revolving credit note							401,085
Warrants Issued in conjunction with debt						1,250,000										9,000,000					7,000,000
Exercise Price per share of warrants issued						3.20										0.38
Proceeds from notes and loans payable		6,900,000		100,000	300,000
Collateral for line of credit				100,000	100,000
Repayment of line of credit	(500,000)		100,735
New Funding																1,000,000	3,000,000				2,000,000
Notes surrendered									1,700,000		1,347,128		1,344,719		2,691,847
Accrued Interest forfeited																15,124
Value of debt converted via warrant conversion		1,054,658													3,102,000
Number of shares issued in warrant conversion (as related to debt)															8,145,486
Repayment of notes payable	(4,691,847)	(50,780)																		4,882,019
Accrued Interest																						$ 21,595

STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	6 Months Ended			0 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Apr. 12, 2013 Underwriters
Common Stock:
Common stock, shares authorized	250,000,000		250,000,000
Common stock, par value	$ 0.001		$ 0.001
Common stock, shares issued	131,212,706		99,784,982
Common stock, shares outstanding	131,212,706		99,784,982
Shares issued in private placement	29,411,765			1,954,587
Share price	$ 1.70
Price per share for private placement shares that may be purchased by underwriter	$ 1.581
Net proceeds from private placement offering (not including shares purchased by underwriters)	$ 45,400,000
Options to purchase shares granted to underwriter	4,411,765
Proceeds from sale of common stock, net	$ 48,512,460			$ 3,100,000

STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)	3 Months Ended		6 Months Ended		0 Months Ended		0 Months Ended			1 Months Ended	6 Months Ended		0 Months Ended		1 Months Ended			0 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jan. 31, 2013 Plato and Associates Note	Jun. 30, 2013 Plato and Associates Note	Mar. 21, 2013 Promissory Notes - June 2012 Notes Issuance	Jun. 19, 2012 Promissory Notes - June 2012 Notes Issuance	Feb. 24, 2012 Promissory Notes - February 2012 Notes Issuance	Mar. 31, 2012 Warrants	Jun. 30, 2013 Warrants	Dec. 31, 2012 Warrants	Jun. 30, 2013 Warrants Sancilio & Company	May 10, 2013 Warrants Sancilio & Company	May 31, 2013 Warrants Sancilio & Company	Jun. 30, 2013 Warrants Lower Range	Jun. 30, 2013 Warrants Upper Range	Jun. 19, 2012 Warrants Tranche 1 Promissory Notes - June 2012 Notes Issuance	Feb. 24, 2012 Warrants Tranche 1 Promissory Notes - February 2012 Notes Issuance	Jun. 19, 2012 Warrants Tranche 2 Promissory Notes - June 2012 Notes Issuance	Feb. 24, 2012 Warrants Tranche 2 Promissory Notes - February 2012 Notes Issuance
Warrants:
Warrants outstanding											14,293,499	12,193,499
Warrant Exercise Price											1.79	1.63				0.24	3.20
Warrants Issued in conjunction with debt					1,250,000			7,000,000	9,000,000									6,000,000		1,000,000
Exercise Price per share of warrants issued					3.20				0.38									2.00	0.38	3.00	0.38
Warrants Fair Value					$ 1,711,956			$ 9,424,982					$ 462,196	$ 405,066					$ 10,505,247		$ 6,124,873
Expected term					6 years			5 years	5 years	5 years			5 years	5 years
Volatility rate					44.29%			44.64%	44.50%	44.81%			45.84%	45.89%
Risk-free rate					0.88%			0.75%	0.89%	1.04%			1.41%	1.12%
Dividend yield					0.00%			0.00%	0.00%	0.00%			0.00%	0.00%
Deferred Financing Costs						1,051,988
Financing costs	395,981		659,968					1,649,890
Amortization of debt discount			1,102,680	1,109,276			885,709		859,647
Warrants Issued - Note Modification																			5,685,300
Warrants Issued - new Funding																					3,314,700
Warrants forfeited															833,000
Warrants granted										31,000	2,100,000				850,000
Warrants vested in period													283,333	283,333
Consulting expense recognized for warrants issued for services										29,736				405,066
Warrants recorded to prepaid expense - short term													154,068
Warrants recorded to prepaid expense - long term													308,128
Unvested warrants													283,334
Unamortized costs warrants											$ 3,995,000

STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)	6 Months Ended	0 Months Ended														6 Months Ended				6 Months Ended	0 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)	Jun. 30, 2013	May 02, 2013 Chairman of the Board	May 02, 2013 Committee Chairs	May 02, 2013 Directors	May 10, 2013 Vesting annually over a 4 year period on anniversary of issuance	Mar. 29, 2013 Vesting annually over a 4 year period on anniversary of issuance	May 06, 2013 Vesting monthly over an 12 month period	Mar. 29, 2013 Vesting monthly over an 12 month period	Mar. 29, 2013 Vesting monthly over an 13 month period	Mar. 29, 2013 Vesting monthly over an 7 month period	Jun. 21, 2013 Stock Options	May 10, 2013 Stock Options	May 06, 2013 Stock Options	Mar. 29, 2013 Stock Options	Jun. 29, 2012 Stock Options	Jun. 30, 2013 Stock Options	Dec. 31, 2012 Stock Options	Mar. 29, 2013 Stock Options Lower Range	Mar. 29, 2013 Stock Options Upper Range	Jun. 30, 2013 Stock Options Robert Finizio, Chief Executive Officer	Apr. 16, 2012 Stock Options Dr. Bernick, Director	Jun. 21, 2013 Stock Options Vesting annually over a 3 year period on anniversary of issuance	Jun. 21, 2013 Stock Options Vesting monthly over an 18 month period	Jun. 21, 2013 Stock Options Vesting monthly over a 3 year period	Jun. 29, 2012 Stock Options Vesting annually over a 4 year period on anniversary of issuance	Jun. 29, 2012 Stock Options Vesting monthly over an 12 month period	Jun. 29, 2012 Stock Options Vesting annually over a 2 year period on anniversary of issuance	Jun. 29, 2012 Stock Options Vesting monthly fromDecember 31 2012	Apr. 16, 2012 Stock Options Committee Chairs	Apr. 16, 2012 Stock Options Directors	Jun. 30, 2013 2009 Long Term Incentive Compensation Plan	Jun. 30, 2013 2012 Stock Incentive Plan
Stock Options:
Shares authorized under incentive plan																															25,000,000	10,000,000
Shares issued under incentive plans																14,655,793	13,733,488														12,934,725	1,625,000
Shares issued for exercise of options, shares	61,372															61,372
Shares issued for exercise of options, value	$ 6,251
Options Granted											632,500	100,000	96,068	180,109	250,000	1,583,677					150,000								75,000	350,000
Weighted Average Exercise Price of options											$ 2.98	$ 2.71	$ 2.96		$ 2.80	$ 1.08	$ 1.16	$ 1.70	$ 2.70		$ 2.55								$ 2.55	$ 2.55
Term of options granted	10 years										10 years	10 years	10 years	10 years	10 years	9 years 10 months 24 days					10 years								10 years	10 years
Options vested in period					50,000	500	96,068	12,500	92,109	43,750		50,000		31,250	50,000							232,500	100,000	300,000	7,500	2,500	115,000	75,000
Stock Options Authorized to the Board of Directors and Key Executives	575,000	225,000	75,000	50,000
Options forfeited																(600,000)				600,000
Unrecognized estimated stock compensation expense	$ 3,695,420
Period for recognition of remaining unrecognized compensation expense	1 year 5 months 26 days

STOCKHOLDERS' EQUITY (Details) (Warrants, USD $)	1 Months Ended	6 Months Ended
STOCKHOLDERS' EQUITY (Details) (Warrants, USD $)	Mar. 31, 2012	Jun. 30, 2013
Warrants
Number of shares under warrant
Warrants outstanding, beginning		12,193,499
Warrants granted	31,000	2,100,000
Warrants exercised
Warrants expired
Warrants cancelled
Warrants outstanding, ending		14,293,499
Vested and Exercisable		12,149,559
Weighted Average Exercise Price
Warrants outstanding, beginning		1.63
Warrants granted		2.72
Warrants exercised
Warrants expired
Warrants cancelled
Warrants outstanding, ending		1.79
Vested and Exercisable		1.67
Weighted Average Remaining Contractual Life
Warrants outstanding, beginning		4 years 9 months 18 days
Warrants granted		7 years 8 months 12 days
Warrants outstanding, ending		4 years 9 months 18 days
Vested and Exercisable		4 years 8 months 12 days
Aggregate Intrinsic Value
Warrants outstanding, beginning		$ 17,971,994
Warrants granted		867,000
Warrants outstanding, ending		17,985,449
Vested and Exercisable		$ 16,540,175

STOCKHOLDERS' EQUITY (Details 1) (Stock Options)	6 Months Ended	12 Months Ended
STOCKHOLDERS' EQUITY (Details 1) (Stock Options)	Jun. 30, 2013	Dec. 31, 2012
Expected dividend yield	0.00%	0.00%
Lower Range
Risk-free interest rate	0.65%	0.61%
Expected Volatility	33.35%	40.77%
Expected term	5 years	5 years
Upper Range
Risk-free interest rate	1.42%	2.23%
Expected Volatility	45.76%	46.01%
Expected term	6 years 3 months	6 years 3 months

STOCKHOLDERS' EQUITY (Details 2) (USD $)	0 Months Ended					6 Months Ended
STOCKHOLDERS' EQUITY (Details 2) (USD $)	Jun. 21, 2013	May 10, 2013	May 06, 2013	Mar. 29, 2013	Jun. 29, 2012	Jun. 30, 2013
Number Options
Options Exercised						(61,372)
Weighted Average Remaining Contractual Life
Granted						10 years
Stock Options
Number Options
Options outstanding, beginning						13,733,488
Options Granted	632,500	100,000	96,068	180,109	250,000	1,583,677
Options Exercised						(61,372)
Options Expired
Options Cancelled						(600,000)
Options outstanding, ending						14,655,793
Vested and exercisable						9,623,443
Weighted Average Exercise Price
Options outstanding, beginning						$ 1.16
Granted						$ 2.79
Exercised
Cancelled
Options outstanding, ending	$ 2.98	$ 2.71	$ 2.96		$ 2.80	$ 1.08
Vested and exercisable						$ 0.60
Weighted Average Remaining Contractual Life
Options outstanding, beginning						7 years 8 months 12 days
Granted	10 years	10 years	10 years	10 years	10 years	9 years 10 months 24 days
Options outstanding, ending						7 years 9 months 18 days
Vested and exercisable						6 years 6 months
Aggregate Intrinsic Value
Options outstanding, beginning						$ 26,804,117
Granted						$ 365,845
Options outstanding, ending						26,038,328
Vested and exercisable						$ 23,208,051

RELATED PARTIES (Details Narrative) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended					6 Months Ended			0 Months Ended	1 Months Ended
RELATED PARTIES (Details Narrative) (USD $)	Oct. 02, 2011	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013 Dr. Bernick, Director	Jun. 30, 2012 Dr. Bernick, Director	Dec. 31, 2012 Dr. Bernick, Director	Jun. 30, 2013 Pernix Therapeutics	Jun. 30, 2012 Pernix Therapeutics	Dec. 31, 2012 Pernix Therapeutics	Nov. 13, 2012 First United Bank Line of Credit	Feb. 28, 2013 First United Bank Line of Credit	Mar. 31, 2011 First United Bank Line of Credit	Jun. 30, 2013 First United Bank Line of Credit
Proceeds from notes and loans payable					$ 6,900,000								$ 100,000	$ 300,000
Collateral for line of credit													100,000	100,000
Debt Interest rate														3.02%
First United line of credit, Personal Guarantees Warrants Issued														613,713
Warrants amended, warrants vested prior to the amendment												358,000
Warrants vested															562,571
Shares exchanged, on a pro rata basis with VitaMed	70,000,000
Revenues						0	1,440
Related Party Receivable						0		1,272
Purchases		463,606	372,370	843,952	708,494				0	96,250
Related Party Accounts Payable									0		308,000
Legal Fee reimbursement due from related parties									$ 171,261		$ 0

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	6 Months Ended
	Jun. 30, 2013 Integer	Jun. 30, 2012
Commitments And Contingencies Details Narrative
Non-cancelable operating lease term	63
Monthly Base rent of leases	$ 28,442
Rental Expense	60,168	56,918
Future minimum lease payments	$ 1,791,900

FIXED ASSETS (Details Narrative) (USD $)	6 Months Ended
FIXED ASSETS (Details Narrative) (USD $)	Jun. 30, 2013	Jun. 30, 2012
Fixed Assets Details Narrative
Depreciation Expense	$ 12,084	$ 15,141

OTHER ASSETS (Details Narrative) (USD $)	6 Months Ended
OTHER ASSETS (Details Narrative) (USD $)	Jun. 30, 2013	Jun. 30, 2012
Other Assets Details Narrative
Amortization of intangible assets	$ 6,509	$ 13,972

OTHER CURRENT LIABILITIES (Details Narrative) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Other Current Liabilities Details Narrative
Dividends Payable, amount per share	$ 0.40	$ 0.40

BUSINESS CONCENTRATIONS (Details Narrative)	6 Months Ended
BUSINESS CONCENTRATIONS (Details Narrative)	Jun. 30, 2013	Jun. 30, 2012
Supplier Concentration Risk
Concentration Risk	98.00%	87.00%
Customer Revenue Concentration Risk
Concentration Risk	62.00%	36.00%

OTHER ASSETS (Details 1) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Intangible assets	$ 345,238	$ 239,555
Patent costs
Intangible assets	337,163	224,971
Website costs
Accumulated amortization	83,668	77,159
Intangible assets	$ 8,075	$ 14,584